DUBLIN–(BUSINESS WIRE)–The “Ankylosing Spondylitis (AS) – Market Insights, Epidemiology, and Market Forecast – 2032” report has been added to ResearchAndMarkets.com’s offering.
This report delivers an in-depth understanding of the AS, historical and forecasted epidemiology as well as the AS market trends in the United States, , EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
The Ankylosing Spondylitis market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted 7MM market size from 2019 to 2032. The Report also covers current AS treatment practice, market drivers, market barriers, SWOT analysis, reimbursement and market access, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.
Geography Covered
- The United States
- EU5 (Germany, France, Italy, Spain, and the United Kingdom)
- Japan
Study Period: 2019-2032
Companies Mentioned
- UCB
- AbbVie
- Pfizer
- Astella
- Amgen
- Pfizer
- Janssen Biotech
- Pozen
- Novartis
- Iroko Pharmaceuticals
- Syntex Pharmaceuticals
- Horizon Pharma
- Eli Lilly and Company
- Kyowa Kirin
- Celgene
- Inmagene Biopharmaceuticals
Key Findings
- The market size of Ankylosing Spondylitis (AS) in the 7MM was USD 4,200 million in 2021.
- In 2021, the market size of AS in the US was 3,224 which is the highest among the 7MM countries.
- The total current market of AS is calculated based on the characterization of the current market into three segments: conventional therapies, biologics, and Cox Inhibitors. It has been estimated that majority of the patients are recommended the use of biologics, as compared to other class drugs.
- From various clinical studies it has been observed that AS involves medication, exercise, physical therapy, good posture practices, and other options such as applying heat/cold to help relax muscles and reduce joint pain. In severe cases, posture correcting surgery may also be an option.
Scope of the Report
- The report covers the descriptive overview of AS, explaining its causes, symptoms, pathophysiology, genetic basis, and currently available therapies.
- Comprehensive insight has been provided into the AS epidemiology and treatment.
- Additionally, an all-inclusive account of both the current and emerging therapies for AS is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
- A detailed review of the AS market; historical and forecasted is included in the report, covering the United States drug outreach.
- The report provides an edge while developing business strategies, by understanding trends shaping and driving the United States AS market.
Report Highlights
- The robust pipeline with novel MOA and oral ROA, increasing incidence, effectiveness of drugs as both mono and combination therapy will positively drive the AS market.
- The companies and academics are working to assess challenges and seek opportunities that could influence AS R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
- Major players are involved in developing therapies for AS. The launch of emerging therapies will significantly impact the AS market.
- Our in-depth analysis of the pipeline assets across different stages of development (phase III and phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.
Ankylosing Spondylitis (AS) Report Insights
- Patient Population
- Therapeutic Approaches
- AS Pipeline Analysis
- AS Market Size and Trends
- Market Opportunities
- Impact of upcoming Therapies
Ankylosing Spondylitis (AS)Report Key Strengths
- 11 Years Forecast
- 7MM Coverage
- AS Epidemiology Segmentation
- Key Cross Competition
- Highly Analyzed Market
- Drugs Uptake
Ankylosing Spondylitis (AS) Report Assessment
- Current Treatment Practices
- Unmet Needs
- Pipeline Product Profiles
- Market Attractiveness
- Market Drivers and Barriers
- SWOT analysis
Reasons to Buy
- The report will help in developing business strategies by understanding trends shaping and driving AS.
- To understand the future market competition in the AS market and Insightful review of the key market drivers and barriers.
- Organize sales and marketing efforts by identifying the best opportunities for AS in the 7MM countries.
- Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.
- Organize sales and marketing efforts by identifying the best opportunities for the AS market.
- To understand the future market competition in the AS market.
For more information about this report visit https://www.researchandmarkets.com/r/1h4wla
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
